Kornimate/medical-research-clean huggingface dataset:
a non-interventional pilot study to explore the role of gut flora in me/cfs

Conditions: Myalgic Encephalomyelitis; Chronic Fatigue Syndrome

Summary: this study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs).

the goal of this research study is to better understand how the genetic information in subject's microbiome correlates to the information provided in surveys and in medical records regarding myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs).

Eligibility criteria:
inclusion criteria: 1. signed informed consent by patient 2. male or female patients age 18 and older. 3. diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs) based on the proposed diagnostic criteria of the national academy of medicine exclusion criteria: 1. refusal by patient to sign informed consent form 2. treatment with antibiotics within 2 weeks prior to screening 3. treatment with probiotics within 6 weeks prior to screening 4. history of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy. 5. postoperative stoma, ostomy, or ileoanal pouch 6. participation in any experimental drug protocol within the past 12 weeks 7. treatment with total parenteral nutrition 8. any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial 9. inability of patient to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire stud
reverse prediction of ion channel remodeling in patients with atrial fibrillation utilizing monophasic action potential and mathematical modeling

Conditions: Atrial Fibrillation

Summary: atrial fibrillation(af) is the most common sustained arrhythmia in humans. the loss of rate-dependent action potential duration(apd) adaptation is one of the characteristics of atrial fibrillation, but detailed understanding of mechanism is limited. thus, we propose to utilize the monophasic action potential recording data from human patients in three groups, control, paroxysmal and persistent atrial fibrillation, and apply reverse engineering method to quantify the extent of electrical remodeling of ionic channel parameters using a mathematical model of atrial cell. our approach will be useful in developing drug targets for ion channels in atrial fibrillation patients.


Eligibility criteria:
inclusion criteria: * patients agreement of consent * af patient age 19-75 * patients who undergoing catheter ablation of atrial fibrillation or supraventricular tachycardia * patient agreement of consent who admission for catheter ablation exclusion criteria: * patients who do not agree with study inclusion * permanent af refractory to electrical cardioversion * af with rheumatic valvular disease * patients with left atrial diameter greater than 60mm * patients with age less than 19 or more 75
long term effect of ait in children

Conditions: Allergy in Children

Summary: the present study will investigate the long term effect of allergen immunotherapy in a real-life study in children with allergy undergoing subcutaneous or sublingual immunotherapy with grass pollen, birch, house dust mites or venom.

the study will include children aged 5- 18 years who are treated with immunotherapy at hans christian andersen children' hospital, odense university hospital. informed consent to be registered in a database and to receive a questionnaire 5 and 10 years after end of treatment are obtained before start of immunotherapy. base line data include information from the patient record: symptoms, medication, blood test and skin prick test results. during treatment effect, medication use, lung function and adverse events are monitored systematically once a year. the questionnaires 5 and 10 years after end of treatment will focus on allergy symptoms, use of medication and asthma symptoms.

Eligibility criteria:
inclusion criteria: treated with allergen immunotherapy at hca children'shospital, odense university hospital - exclusion criteria: received less than 12 months of treatment with allergen immunotherapy -
diagnostic yield of fna needle and fnb needle for autoimmune pancreatitis

Conditions: Autoimmune Pancreatitis

Summary: the aim of this study is to compare the diagnostic accuracy of two eus-guided tissue acquisition devices; the 19g echotip ultra fine needle aspiration (fna) device and the 20g echotip procore fine needle biopsy (fnb) device for the diagnosis of autoimmune pancreatitis.

endoscopic ultrasound (eus)-guided tissue acquisition has emerged as a valuable method to diagnose autoimmune pancreatitis (aip) and exclude malignancy. during endoscopic ultrasound (eus), tissue samples can be obtained for pathological evaluation with different devices. previous studies suggest 19-gauge fine needle aspiration (fna) needle provides a reliable specimen for diagnosis of aip. however tissue architecture and cell morphology are essential for accurate pathological assessment. therefore, pathologists generally prefer a histological specimen. fine needle biopsy (fnb) has the advantage of obtaining a histological specimen, which may lead to better diagnostic performance. however, the superiority of histology over cytology in eus-guided tissue sampling for diagnosis of aip has not been proven yet. in this study, we aim to compare the diagnostic accuracy of two eus-guided tissue acquisition devices; the 19g echotip ultra fine needle aspiration (fna) device and the 20g echotip procore fine needle biopsy (fnb) device for the diagnosis of autoimmune pancreatitis.

Eligibility criteria:
inclusion criteria: * patients referred for eus-guided tissue acquisition because of clinical suspicion of aip * age \> 18 years * written informed consent exclusion criteria: * known bleeding disorder that cannot be sufficiently corrected with co-fact or fresh frozen plasma (ffp) * use of anticoagulants that cannot be discontinued in order to guarantee an inr below 1.5 * previous inclusion in the current study * pregnancy
the effect of intraoperative dexmedetomidine on postoperative morphine requirements after breast cancer surgery

Conditions: Morphine Consumption

Summary: dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. in previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflammatory responses. as patients receiving breast surgeries are especially vulnerable to postoperative nausea/ vomiting, the dosage of narcotics and associated complications were concerned for not only comfortness but also postoperative oral intake and discharge. the invetigators aimed to compare the effects of dexmedetomidine infusion versus placebo on postoperative narcotics requirement, complications, and oral intake.

dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. in previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflammatory responses. as patients receiving breast surgeries are especially vulnerable to postoperative nausea/ vomiting, the dosage of narcotics and associated complications were concerned for not only comfortness but also postoperative oral intake and discharge. the invetigators aimed to compare the effects of dexmedetomidine infusion versus placebo on postoperative narcotics requirement, complications, and oral intake. the participantss under general anesthesia and aged from 30 to 65 years old will be enrolled. all subjects were randomized into the dexmedetomidine or placebo group. they received placebo (group p, n = 30) or dexmedetomidine (loading dose of 1 μg kg-1 followed by 0.5 μg kg-1 h-1) (group d, n = 30) to the end of surgery. data collected included intraoperative and postoperative opioid consumption. postoperative questionare including ponv, pain intensity, i-feed questionnaire. prospective analysis will be performed on the prospectively collected data. we expected to examine if intraoperative dexmedetomidine decreases the postoperative opioid consumption and associated complications, and enhances the gastrointestinal recovery and oral intake with narcotic-sparing effect.

Eligibility criteria:
inclusion criteria: * patients who fulfill the criteria of breast cancer under general anesthesia. exclusion criteria: * major systemic disease, such as congestive heart failure, liver cirrhosis, end stage renal disease and malignancy. * patients who have the risk of difficult ventilation or intubation. * pregnant women. * coagulopathy.
laparoscopic or conventional mesh repair of incisional and umbilical hernia

Conditions: Incisional Hernia; Umbilical Hernia

Summary: the aim of this study is to compare immediate and long-term (24 months) results of laparoscopic and open mesh repair of incisional and umbilical hernia.

the aim of this study is to compare immediate and long-term (24 months) results of laparoscopic and open mesh repair of incisional and umbilical hernia. five hundred patients will be included in this randomized, multicentric trial. hypotheses are that laparoscopic approach: 1- reduces immediate parietal complications without increasing intra abdominal septic complications 2- is less invasive and also reduces patients' hospital stay and recovery time; 3- has the same efficacy, than open approach.

Eligibility criteria:
inclusion criteria: * age \> 18 * incisional or umbilical hernia over 2 cm and less than 6 cm in diameter exclusion criteria: * patients with a complicated incisional (pain, occlusion, cutaneous necrosis), irreductible painless incisional or umbilical hernia will not be considered as a complication * patients with a recurrence of incisional hernia * patients with an incisional or umbilical hernia whose lateral edges are located so that fixation of the mesh (which must extend beyond the 4 to 5 cm) is not possible * pregnant women * patients with hiv therapy * patients with cirrhotic ascites or other signs of hepatic insufficiency (bilirubin\> 35 micromol / l; tp \< 55%) or significant thrombocytopenia (\< 60 000 platelets) * patients with a contra indication for laparoscopy * patients with a life expectancy \< one year, or whose mobility within two years of treatment will damage proper monitoring * patients unable to understand information about the protocol

Keywords: laparoscopy incisional hernia umbilical hernia mesh repair postoperative complications
adding polyphenol-rich pulses to daily diet improves skin health by reshaping the skin microbiome

Conditions: Healthy

Summary: skin health is influenced by the microbiome, lipids, oxidative stress, inflammation, and uv exposure. a 14-week trial with 50 women aged 45-65 will test if polyphenol-rich pulses improve skin health by affecting these factors. using a white rice control diet, the study will measure skin parameters and analyze correlations with changes in lipids and microbiome, potentially proving the benefits of pulses.

human skin is the largest organ in the body. the slow deterioration of skin appearance and its barrier function are the most prominent signs of human ageing. cutaneous factors (microbiome and lipids) have immediate and direct impacts on skin health and functions. intrinsic factors (oxidative stress and inflammation) and extrinsic ones (mostly uv irritation due to sun exposure) affect the skin chronically. our preliminary research showed that six weeks of cranberry juice intake improved part of women's skin health parameters and decreased oxidative stress. its activities on the skin correlated with changes in skin microbiome and epidermal lipids. pulses, especially lentils and beans, are rich sources of polyphenols and fibers. however, there is no clinical evidence on whether adding a serving of cooked mixed pulses with high polyphenol content (lentils, red kidney bean, black beans, and pinto beans) to the diet affects skin health and the underlying causes of skin aging. women make over 90% of the decisions on food purchases for their families. skin health is a major concern for women because skin aging becomes visibly noticeable after age 30. the investigators hypothesize that polyphenol-rich pulses improve skin health by reshaping the cutaneous microbiome and lipids and suppressing inflammation and oxidative stress. this hypothesis will be tested in a 14-week clinical trial in 50 women aged 45-65 using a randomized controlled parallel design. the control diet will be formulated using white rice to match the calories and macronutrients of mixed pulses.

Eligibility criteria:
inclusion criteria: * bmi (18.5-29.9) * body weight ≥110 pounds * fitzpatrick skin type 2 and 3. exclusion criteria: * pregnancy * breast-feeding * impaired fasting glucose * frequent alcohol use * history of skin cancer * sunbathing and the use of tanning bed, intake of vitamin/mineral supplements * habitual high intake of fruits (≥ 2 cups daily) * intake of medication that might influence the outcome of the study

Keywords: pulse women skin health
covid-19-related health and practices among dental hygienists

Conditions: SARS-CoV Infection; Anxiety; Depression; Occupational Problems; Severe Acute Respiratory Syndrome; Coronavirus Infection

Summary: as dental practices reopen their practices during a global pandemic, the risk of 2019 novel coronavirus (covid-19) infection that dental hygienists face in providing dental care remains unknown. estimating the occupational risk of covid-19, and producing evidence on the types of infection control practices and dental practices that may affect covid-19 risk, is therefore imperative. these findings could be used to describe the prevalence and incidence of covid-19 among dental hygienists, determine what infection control steps dental hygienists take over time, describe dental hygienists' employment during the covid-19 pandemic, and estimate whether infection control adherence in dental practice is related to covid-19 incidence.


Eligibility criteria:
inclusion criteria: * dental hygienist * licensed in the united states * 18 years of age or older exclusion criteria: * not employed as a dental hygienist as of march 1, 2020
efficacy and safety phase ii study of sr-t100 to treat actinic keratosis

Conditions: Actinic Keratosis

Summary: this phase ii study is to evaluate the efficacy of sr-t100 gel with 2.3% of sm in solanum undatum plant extract in patient with actinic keratosis (ak).


Eligibility criteria:
inclusion criteria: 1. male or female; aged ≥ 18 years old. 2. patient who accepts to enter the study by signing written informed consent. 3. patient has 4 to 8 clinically diagnosed, discrete, non-hyperkeratotic, non-hypertrophic ak, located with or without a contiguous 25cm2 areas. 4. patient allows biopsy to be performed on selected lesion. 5. patient agrees to apply the study medication on prescribed treatment area with an occlusive dressing at least 20 hours per day. 6. patient agrees photographs to be taken on selected lesion and used as part of the study data package. 7. patient in good general health condition (performance status ≤ 2 eastern cooperative oncology group (ecog). 8. sexually active female patient with child-bearing potential must take reliable contraception method(s) during the participation of the study. exclusion criteria: 1. patient with recurrent invasive squamous cell carcinoma (scc). 2. patient has grossly suspicious or inflamed lymph nodes on physical examination. 3. patient has evidence of clinically significant or unstable medical conditions. 4. patient has any skin condition in the treatment area that may be made worse by treatment. 5. patient currently uses or had used on the treatment area(s) otc retinol products, corticosteroids, cryosurgery, curettage, 5-fluorouracil (5-fu), imiquimod, topical diclofenac, retinoids, or other topical ak treatments (such as laser abrasion, dermabrasion, glycolic acids, or chemical peels) 28 days prior to screening visit. 6. patient had received systemic cancer chemotherapy or immunosuppressant; on the target evaluation area that psoralen plus uva therapy, uvb therapy were treated 6 months prior to screening visit. 7. patient currently uses or has used prednisone and/or prednisolone (≥ 10 mg or the equivalent) more than 2 weeks continuously within 12 weeks prior to randomization visit. 8. engaging in activities involving excessive or prolonged exposure to sunlight. 9. history of allergy or sensitivity to related compounds or other components of the investigational product formulation. 10. woman who is pregnant, lactating or planning to become pregnant during the study. 11. patient used any investigational drug within 8 weeks prior to the screening visit.

Keywords: actinic keratosis ak
development of a biomarker to predict the efficacy of anti-angiogenic therapy in ovarian cancer

Conditions: Epithelial Ovarian Cancer

Summary: epithelial ovarian cancer (eoc) is a highly angiogenic tumor and drug targeting of angiogenesis is effective in some selected groups of eoc patients. however, no biomarkers are available to predict the effectiveness of this expensive therapy.investigators believe that multimerin-2, an extracellular matrix molecule, could serve as a biomarker that can address this clinical need. multimerin-2 is deposited throughout the vasculature and its expression in eoc-associated vessels is frequently lost, in part due to increased degradation. multimerin-2 sequesters vegfa and other angiogenic factors and their release upon degradation of multimerin-2 could underlie resistance to anti-angiogenic therapy. indeed, fragments of degradation of multimerin-2 are found in high concentrations in sera of eoc patients. furthermore, the loss of multimerin-2 impairs the function of the vessels, and this could negatively affect the delivery of the drug and the efficacy of the treatment. with the aim of predicting the efficiency of anti-angiogenic therapy, researchers will evaluate the angiogenic properties and expression of multimerin-2 in eoc tumors, and develop a new multimerin-2-based biomarker detectable by liquid biopsy, in order to manage eoc patients in a targeted manner based on the biological characteristics of their tumor.


Eligibility criteria:
inclusion criteria: 1. female patients aged ≥18 years 2. histological diagnosis of epithelial carcinoma of the ovary or fallopian tubes or primary carcinoma of the peritoneum, including mixed mullerian tumours. 3. stage iiib, iiic or iv 4. performance status 0-2 according to ecog 5. availability of tumor tissue samples and biological fluids for molecular analyses 6. informed consent for the collection, storage and use of biological material for the cro biobank (as specified in the consent of the cro biobank, rev 2 of 03/10/2016), signed and obtained before surgery for suspected eoc. exclusion criteria: 1. ovarian tumors of low malignant potential (i.e. borderline tumors) 2. other malignacies within the last 5 years except carcinoma in situ of the cervix or early stage squamous cell or basal cell carcinoma of the skin, as long as they are adequately treated. 3. active infection or uncontrolled chronic inflammatory disease
effectiveness of paritaprevir/r - ombitasvir, ± dasabuvir, ± ribavirin in patients with chronic hepatitis c - an observational study

Conditions: Chronic Hepatitis C

Summary: the interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (abbvie regimen) ± ribavirin (rbv) for the treatment of chronic hepatitis c (chc) has been shown to be safe and effective in randomized controlled clinical trials with strict inclusion and exclusion criteria under well controlled conditions. this observational study is the first effectiveness research examining the abbvie regimen ± rbv, used according to local label, under real world conditions in kuwait in a clinical practice patient population.


Eligibility criteria:
inclusion criteria: * treatment-naïve or -experienced adult male or female participants with confirmed chc, genotype 1 or 4, receiving combination therapy with the interferon-free abbvie regimen ± rbv according to standard of care and in line with the current local label. * if rbv is co-administered with the abbvie regimen, it has been prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy). * participant must not be participating or intending to participate in a concurrent interventional therapeutic trial. exclusion criteria: * participant must not be participating or attending in a concurrent interventional therapeutic trial.

Keywords: paritaprevir/r - ombitasvir, ± dasabuvir sustained virological response chronic hepatitis c genotype 4 observational study chronic hepatitis c genotype 1 chronic hepatitis c
immediate axillary plasty with a pedicled muscle flap for breast cancer related lymphedema prevention

Conditions: Lymphedema; Breast Neoplasm

Summary: the purpose of this comparable cohort study is to evaluate the efficacy and safety of immediate axillary plasty with pedicled partial latissimus dorsi muscle flap for lymphedema prevention in breast cancer patients who are undergoing axillary dissection.

upper limb lymphedema is the main complication of axillary dissection. it is estimated that as many as 50% of patients undergoing lymph node dissection go on to develop lymphedema, with significantly decreased quality of life with frequent infections, decreased range of motion, and a cosmetic deformity. the treatment of lymphedema was be frustrated by technical difficulties and gave rise to a heavy budget burden. some retrospective studies revealed that immediate and delayed breast reconstruction with lattismus dorsi flap brought unexpected relief to the upper limb lymphedema. the current study was composed to assess whether transferring a pedicled partial latissimus dorsi muscle flap to the axilla would prevent the occurrence of post-mastectomy lymphedema. this prospectively designed cohort study have two parallel arms. patients undergoing axillary dissection would be recruited to one of the two groups, according their own preference.

Eligibility criteria:
inclusion criteria: * patients undergoing axillary lymph node dissection exclusion criteria: * prior iplateral upper limb edema * plan for breast or axillary reconstruction * the thoracodorsal vessel damage * muscle flap volume too low

Keywords: breast neoplasm lymphedema autologous flap lattismus dorsi flap
further cardiovascular outcomes research with pcsk9 inhibition in subjects with high risk coronary artery disease (forward)

Conditions: Dyslipidemia; High Risk Coronary Artery Disease

Summary: the primary objective was to evaluate the effect of treatment with evolocumab on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with high risk coronary artery disease.


Eligibility criteria:
inclusion criteria: * male or female ≥ 18 years of age * coronary artery disease at high risk (syntax score ≥ 33) * patients had to have a fasting ldl cholesterol level of 1.4 mmol per liter while they had been taken an optimized regimen of lipid-lowering therapy for at least 4 weeks, which was defined as preferably a high intensity statin but must have been at least atorvastatin at a dose of 20 mg daily or its equivalent, with or without ezetimibe. exclusion criteria: * new york heart association (nyha) class iii or iv, or last known left ventricular ejection fraction \< 30% * uncontrolled hypertension * uncontrolled or recurrent ventricular tachycardia * untreated hyperthyroidism or hypothyroidism * homozygous familial hypercholesterolemia * ldl or plasma apheresis

Keywords: high cholesterol treatment for high cholesterol lowering cholesterol lowering high cholesterol hypercholesterolemia